Cardiol Therapeutics (CRDL) Competitors $1.42 +0.05 (+3.65%) (As of 09:51 AM ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestTrends CRDL vs. GHRS, RGNX, TSHA, ALMS, AKBA, CYRX, PROC, DSGN, BTMD, and NGNEShould you be buying Cardiol Therapeutics stock or one of its competitors? The main competitors of Cardiol Therapeutics include GH Research (GHRS), REGENXBIO (RGNX), Taysha Gene Therapies (TSHA), Alumis (ALMS), Akebia Therapeutics (AKBA), Cryoport (CYRX), Procaps Group (PROC), Design Therapeutics (DSGN), biote (BTMD), and Neurogene (NGNE). These companies are all part of the "pharmaceutical products" industry. Cardiol Therapeutics vs. GH Research REGENXBIO Taysha Gene Therapies Alumis Akebia Therapeutics Cryoport Procaps Group Design Therapeutics biote Neurogene GH Research (NASDAQ:GHRS) and Cardiol Therapeutics (NASDAQ:CRDL) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their risk, community ranking, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations. Do analysts prefer GHRS or CRDL? GH Research currently has a consensus target price of $35.67, suggesting a potential upside of 321.59%. Cardiol Therapeutics has a consensus target price of $8.75, suggesting a potential upside of 538.69%. Given Cardiol Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Cardiol Therapeutics is more favorable than GH Research.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GH Research 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Cardiol Therapeutics 0 Sell rating(s) 0 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 3.20 Which has preferable valuation and earnings, GHRS or CRDL? Cardiol Therapeutics has higher revenue and earnings than GH Research. GH Research is trading at a lower price-to-earnings ratio than Cardiol Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGH ResearchN/AN/A-$35.59M-$0.79-10.71Cardiol Therapeutics$60K1,865.55-$20.84M-$0.39-3.51 Is GHRS or CRDL more profitable? GH Research's return on equity of -20.29% beat Cardiol Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets GH ResearchN/A -20.29% -19.49% Cardiol Therapeutics N/A -194.40%-129.07% Do institutionals and insiders hold more shares of GHRS or CRDL? 56.9% of GH Research shares are owned by institutional investors. Comparatively, 12.5% of Cardiol Therapeutics shares are owned by institutional investors. 41.6% of GH Research shares are owned by insiders. Comparatively, 5.3% of Cardiol Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in GHRS or CRDL? GH Research received 1 more outperform votes than Cardiol Therapeutics when rated by MarketBeat users. Likewise, 72.73% of users gave GH Research an outperform vote while only 62.16% of users gave Cardiol Therapeutics an outperform vote. CompanyUnderperformOutperformGH ResearchOutperform Votes2472.73% Underperform Votes927.27% Cardiol TherapeuticsOutperform Votes2362.16% Underperform Votes1437.84% Does the media refer more to GHRS or CRDL? In the previous week, GH Research and GH Research both had 1 articles in the media. GH Research's average media sentiment score of 1.76 beat Cardiol Therapeutics' score of 0.44 indicating that GH Research is being referred to more favorably in the media. Company Overall Sentiment GH Research Very Positive Cardiol Therapeutics Neutral Which has more risk & volatility, GHRS or CRDL? GH Research has a beta of 0.78, meaning that its share price is 22% less volatile than the S&P 500. Comparatively, Cardiol Therapeutics has a beta of 0.83, meaning that its share price is 17% less volatile than the S&P 500. SummaryCardiol Therapeutics beats GH Research on 9 of the 16 factors compared between the two stocks. Ad Porter & CompanyHow to piss off your liberal friends… and profit from itElon Musk has just exposed the “energy grift” of America in a recent tweet to his platform, X. And people are slowly starting to wake up to the Deep State’s lies.To get the full details on the fake “energy crisis” of America, watch this now Get Cardiol Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CRDL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CRDL vs. The Competition Export to ExcelMetricCardiol TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$111.93M$2.98B$5.19B$9.32BDividend YieldN/A1.85%4.78%4.06%P/E Ratio-3.5146.24128.2217.54Price / Sales1,865.55420.891,259.00139.66Price / CashN/A182.1341.2237.95Price / Book4.283.924.884.92Net Income-$20.84M-$42.03M$119.69M$225.78M7 Day Performance-4.20%-3.37%16.64%-1.56%1 Month Performance-23.46%7.95%16.32%6.68%1 Year Performance63.23%21.00%35.37%22.48% Cardiol Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CRDLCardiol Therapeutics2.3164 of 5 stars$1.42+3.6%$8.75+516.2%+58.4%$116.02M$60,000.00-3.6420Gap DownGHRSGH Research1.9124 of 5 stars$8.20+5.9%$35.67+335.0%+51.3%$426.63MN/A-9.8010Positive NewsRGNXREGENXBIO4.6208 of 5 stars$8.57+3.5%$35.27+311.6%-57.6%$424.56M$90.24M-1.65344TSHATaysha Gene Therapies3.4124 of 5 stars$2.03-1.9%$6.63+226.4%+24.5%$416.03M$15.45M3.29180ALMSAlumisN/A$8.63+2.9%$26.83+210.9%N/A$407.53MN/A0.00N/ANews CoveragePositive NewsAKBAAkebia Therapeutics3.538 of 5 stars$1.86+0.5%$7.50+303.2%+62.6%$405.82M$169.88M-8.15167CYRXCryoport3.2157 of 5 stars$7.58-1.4%$12.50+64.9%-48.9%$374.69M$226.11M-2.321,170Short Interest ↓Positive NewsPROCProcaps Group0.7513 of 5 stars$3.21+33.2%N/A+19.8%$362.15M$414.10M5.105,500News CoverageHigh Trading VolumeDSGNDesign Therapeutics0.7899 of 5 stars$6.37+13.8%$7.00+9.9%+144.1%$360.68MN/A-7.1840Positive NewsBTMDbiote3.4078 of 5 stars$6.60+3.6%$9.11+38.0%+24.5%$358.62M$193.06M24.77194Analyst ForecastNews CoveragePositive NewsGap UpNGNENeurogene3.9663 of 5 stars$24.03+2.2%$60.83+153.2%N/A$356.97M$925,000.000.0090Positive News Related Companies and Tools Related Companies GHRS Alternatives RGNX Alternatives TSHA Alternatives ALMS Alternatives AKBA Alternatives CYRX Alternatives PROC Alternatives DSGN Alternatives BTMD Alternatives NGNE Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CRDL) was last updated on 12/18/2024 by MarketBeat.com Staff From Our PartnersUncover the Top Gold Stock of the Bull MarketGold Stocks Are Surging—Is West Red Lake Gold Mines Your Next Profit Play?Huge Alerts | SponsoredHow this >10-cent coin is going to outperform Bitcoin Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredHealthcare Takes A Big Step Forward With The Help of A.I.To date, we've seen baseline AI models lay the groundwork. Tools like ChatGPT are useful, but they are still s...Wall Street Star | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored50-year Wall Street legend: “Sell this tech stock NOW”Something very strange is happening to U.S. stocks following President Trump's victory... And this could s...Chaikin Analytics | SponsoredThis drone stock is setting up to transform medical supply deliveryDrone stocks are on a tear, with certain symbols seeing gains as high as 300% over just a matter of weeks.The Tomorrow Investor | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cardiol Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cardiol Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CRDL Stock Alerts